Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose decitabine in intermediate-2 and high-risk myelodysplastic syndrome
ChiCTR-ONC-13004271Phase 4Completed
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of decitabine in myelodysplastic syndrome (MDS), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: overall response rate. Started Jan 2014; status: completed.
02
Drugs
decitabine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR-ONC-13004271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-13004271.